Start with its own history
At 64.50×, ATRI is 195388.2% above its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.

Current valuation, historical context, and peer comparisons.
Current P/E ratio
64.50×
195388.2% abovethe 10-year annual average
Price and EPS in quote currency. Calculation details
Investors are paying 64.50 for every 1 of reported earnings per share.
Annual period-end data · 25 observations
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2023 | 0.03× | +20.4% |
| Dec 31, 2022 | 0.03× | -26.2% |
| Dec 31, 2021 | 0.04× | +5.4% |
| Dec 31, 2020 | 0.04× | -3.2% |
| Dec 31, 2019 | 0.04× | -5.4% |
| Dec 31, 2018 | 0.04× | +26.0% |
| Dec 31, 2017 | 0.03× | -5.2% |
| Dec 31, 2016 | 0.03× | +37.9% |
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2015 | 0.02× | +1.6% |
| Dec 31, 2014 | 0.02× | +6.9% |
| Dec 31, 2013 | 0.02× | +34.0% |
| Dec 31, 2012 | 0.02× | -10.2% |
| Dec 31, 2011 | 0.02× | +7.7% |
| Dec 31, 2010 | 0.02× | -5.5% |
| Dec 31, 2009 | 0.02× | +50.6% |
| Dec 31, 2008 | 0.01× | -27.9% |
| Dec 31, 2007 | 0.02× | -87.4% |
| Dec 31, 2006 | 0.13× | -4.0% |
| Dec 31, 2005 | 0.14× | +14.0% |
| Dec 31, 2004 | 0.12× | -18.1% |
| Dec 31, 2002 | 0.15× | +88.0% |
| Dec 31, 2001 | 0.08× | -99.3% |
| Dec 31, 2000 | 10.85× | -10.2% |
| Dec 31, 1999 | 12.08× | +1.2% |
| Dec 31, 1998 | 11.94× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
ATRI This stockAtrion Corporation | 64.50× |
CSIICardiovascular Systems, Inc. | N/M |
CMRXChimerix, Inc. | N/M |
CDMOAvid Bioservices, Inc. | N/M |
ICPTIntercept Pharmaceuticals, Inc. | 5.57× |
ASLNASLAN Pharmaceuticals Limited | N/M |
PETQPetIQ, Inc. | 423.80× |
ICVXIcosavax, Inc. | N/M |
HARPHarpoon Therapeutics, Inc. | N/M |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
At 64.50×, ATRI is 195388.2% above its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
The median of the 2 positive peer ratios above is 214.69×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore Wisesheets=WISE("ATRI", "PE Ratio", "LQ")Share price 459.92 ÷ EPS 7.13 = 64.50×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Not supplied; this is not a real-time trading quote.
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
The essentials behind the numbers.